InMed Pharmaceuticals Free Cash Flow (FCF) History (INM)

InMed Pharmaceuticals reported −$7.0M in free cash flow for fiscal 2024, an increase of $448,088 from the previous fiscal year, with a free cash flow margin of −152.14%.

View full InMed Pharmaceuticals company overview

InMed Pharmaceuticals free cash flow by year

InMed Pharmaceuticals annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20242024-06-30−$7.0M$448,088—−152.14%
20232023-06-30−$7.4M$8.2M—−544.99%
20222022-06-30−$15.6M−$5.8M—−1143.90%
20212021-06-30−$9.8M−$2.4M—−514.30%
20202020-06-30−$7.4M———

InMed Pharmaceuticals free cash flow growth trends

InMed Pharmaceuticals's latest reported quarter, Q3 2024, generated −$1.9M in free cash flow.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review InMed Pharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about INM yet. Start the conversation.

Write the first post